Lactose is the major carbohydrate component of milk and other dairy products. Digestion of lactose is mediated by lactase (LCT), an enzyme uniquely expressed in epithelial cells of the small intestine. In mammals, LCT expression initiates before birth, remains high during the nursing period and then progressively declines after weaning, thus resulting in lactase nonpersistence 1,2 . However, some humans are lactase persistent, and their levels of LCT mRNA, and consequently LCT activity, remain high in adulthood, especially in the jejunum of the small intestine. Human lactase nonpersistence is the ancestral state of LCT regulation, and over 65% of humans worldwide are lactose intolerant 3 . Despite the prevalence of lactase nonpersistence in humans and other mammals, the underlying molecular mechanisms are not well understood.
a r t i c l e s
Lactose is the major carbohydrate component of milk and other dairy products. Digestion of lactose is mediated by lactase (LCT), an enzyme uniquely expressed in epithelial cells of the small intestine. In mammals, LCT expression initiates before birth, remains high during the nursing period and then progressively declines after weaning, thus resulting in lactase nonpersistence 1, 2 . However, some humans are lactase persistent, and their levels of LCT mRNA, and consequently LCT activity, remain high in adulthood, especially in the jejunum of the small intestine. Human lactase nonpersistence is the ancestral state of LCT regulation, and over 65% of humans worldwide are lactose intolerant 3 . Despite the prevalence of lactase nonpersistence in humans and other mammals, the underlying molecular mechanisms are not well understood.
To date, interindividual differences in LCT expression in human adults have been attributed solely to DNA-sequence variation upstream of LCT. In particular, the C/T(−13910) single-nucleotide polymorphism (SNP) (also known as rs4988235) in intron 13 of the minichromosome maintenance complex component 6 (MCM6) gene is associated with the phenotypes of lactase persistence and nonpersistence in European populations 4 . Lactase persistence in Europe is attributed to the T(−13910) allele, which is part of an extended conserved >500-kb haplotype that has been under strong directional selection for the past 3,000-7,500 years (refs. 5-9) . This and other nearby genetic polymorphisms associated with LCT expression have also been detected in other ethnic groups 3, [10] [11] [12] , and lactase persistence across populations originated on several different haplotype backgrounds [10] [11] [12] . However, in non-Europeans, these SNPs do not fully explain lactase persistence, and certain individuals within African populations exhibit lactase persistence in the absence of known LCT-associated variants 3, 10 . Although reporter assays examining LCT promoter induction and gel shifts [13] [14] [15] , as well as transgenic mouse experiments 16 , support the importance of SNP C/T(−13910) in LCT regulation in European populations, the reported differences between allelic variants are modest (the T(−13910) variant shows an ~1.5-fold-higher activity than that of the ancestral variant) 15 . These observations suggest that, in addition to SNPs, there may be other factors contributing to the differences in LCT mRNA in lactasepersistent and lactase-nonpersistent individuals. It is also unclear what molecular mechanisms account for the age-dependent changes in LCT expression, from very high expression in infancy to substantial downregulation in most adults. Because DNA sequence is stable, more dynamic regulatory systems must be involved in the temporal dimension of lactase nonpersistence.
Epigenetic modifications of DNA and histone proteins may contribute to lactase nonpersistence because they effectively regulate gene transcription 17 , differ markedly across tissues and cell types 17, 18 and also change in the same individual over time 19, 20 . Indeed, evidence suggests that many manifestations of aging, including age-dependent diseases, have an epigenetic basis 17, 21, 22 . Here, we set out to conduct what is to our knowledge the first investigation examining the extent to which epigenetic processes mediate the age-dependent and cell-type-specific downregulation of LCT that results in lactase nonpersistence. In this study, we performed chromosome-wide profiling of DNA modifications (consisting of methylation and other epigenetic cytosine modifications), by using high-density tiling microarrays, as well as targeted bisulfite-sequencing-based interrogation of the human and mouse lactase genes in intestinal cells and other tissues. We detected changes in DNA-modification densities at several distinct regulatory elements that direct the gradual decline in lactase gene expression after infancy in mammals. We then explored how genetic factors can affect age-specific changes in epigenetic modifications and found that SNP C/T(−13910)-containing haplotypes contribute to the epigenetic aging of the LCT-MCM6 region. To validate the epigenetically controlled regulatory elements for the lactase gene, we used RNA interference (RNAi) in human tissue culture and CRISPR-Cas9-induced genetic deletions in mice. Our study revealed that lactase nonpersistence results from the accumulation of transcriptionally suppressive epigenetic changes in haplotypes carrying the SNP C(−13010) allele, whereas T(−13910)-containing haplotypes escape from epigenetic inactivation and facilitate lactase persistence.
RESULTS

Chromosome-wide investigation of lactase-gene regulation
To explore epigenetic contributions to lactase nonpersistence and persistence, we obtained surgical jejunum samples from unrelated human adults (Supplementary Fig. 1a ) and isolated villi enterocytes (intestinal epithelial cells) 23 from the jejunum (Supplementary Fig. 1b ). Across individuals, there was a wide range of steady-state LCT mRNA levels differing up to 29-fold (Supplementary Fig. 1c) .
We then explored chromosome-wide DNA-modification patterns in the human enterocyte samples (cohort 1, n = 56 individuals). We enriched for the unmodified DNA fraction by using the mTAG-click method 24 and subsequently interrogated the samples on Affymetrix high-density human tiling arrays. The arrays surveyed human chromosome 2, which contains LCT (and the same array also contained chromosomes 9 and 19). Examination across chromosome 2 identified five probes that exhibited a significant correlation between steady-state LCT mRNA and the density of unmodified cytosines (false discovery rate (FDR) q = 0.017, R 2 = 0.28-0.32). All five probes clustered in an ~170-bp region of LCT exon 1-intron 1, and higher DNA-modification densities were associated with lower LCT mRNA levels ( Fig. 1 and Supplementary Table 1) . As expected, we detected no significant associations between LCT mRNA levels and DNA modifications on chromosomes 9 and 19 ( Supplementary  Fig. 2 ). DNA modifications in the jejunum lacking enterocytes also did not exhibit any significant correlations with LCT mRNA (Supplementary Fig. 3) .
We next investigated whether DNA-modification changes are involved in the age-related decline in expression of the lactase gene.
In this experiment, we compared chromosome-wide DNA-modification profiles of jejunal enterocytes of infant and adult mice (postnatal days 6 and 60, respectively). Similarly to humans with lactase nonpersistence, mice show high intestinal lactase activity at birth and a gradual decrease after infancy 25 . Indeed, we found that Lct mRNA expression in the jejuna of inbred C57BL/6N adult mice at postnatal day 60 was decreased by three-fold compared with those of infant mice at postnatal day 6 (P <10 −4 ; Supplementary Fig. 4a ). For the epigenetic analysis, we used the mTAG-click method to enrich for the unmodified DNA fraction in jejunal enterocyte samples from infant and adult mice, and then performed interrogation on mouse tiling microarrays. We detected that 0.4% of probes in mouse chromosome 1, which contains Lct, exhibited significant differential DNA modification between the two age groups (11, 206 probes, FDR q <0.01; Supplementary  Fig. 4b and Supplementary Data Set 1). Of these differentially modified probes, 30 probes mapped to within 100 kb of Lct, clustering into three regions: Lct intron 2-exon 3; intron 8-exon 9; and exon 10 (region size, ~60-700 bp; fold change, 1.36-2.25; Supplementary  Fig. 4b and Supplementary Table 1) . At all these regions, adult animals, compared with infants, demonstrated significantly greater densities of modified cytosines (FDR q <0.01). These results signify an inverse relationship between DNA modification and Lct mRNA levels. Thus, chromosome-wide analysis revealed epigenetically modified regions in the lactase genes of both mice and humans, and these regions may be important for transcriptional regulation and the establishment of lactase nonpersistence.
Interindividual and cell-type-specific LCT regulatory sites To complement the broad but relatively low resolution of the microarraybased approach, we fine-mapped the extended human LCT region by using bisulfite padlock-probe sequencing 26 . We designed 466 padlock probes covering an ~100-kb genomic region encompassing LCT (49 kb) and MCM6 (37 kb). In addition to samples from the first cohort used in the microarray experiment, jejunum samples from a second cohort (n = 59 individuals) was added to this investigation, for a total of 115 samples (Supplementary Fig. 1a) . We first examined the regions mediating human interindividual differences in LCT. To do so, we performed correlation analysis between DNAmodification densities and LCT mRNA levels. In enterocytes, we detected significant inverse correlations between DNA-modification density and steady-state LCT mRNA levels at 11 CpG sites (P <0.01-10 −10 after Bonferroni correction). These 11 CpGs clustered 
MCM6
LCT exon 1-intron 1 Figure 1 Chromosome-wide scan to detect epigenetically modified regions associated with LCT regulation in humans. DNA modifications across the entire human chromosome containing the LCT gene, investigated in jejunal enterocytes by a tiling-array approach. Statistical significance of correlations (y axis) between the density of unmodified cytosines across human chromosome 2 (x axis) and LCT steady-state mRNA levels in enterocytes (n = 56 individuals). The single region exhibiting significant correlation after chromosome-wide correction for multiple testing maps to LCT exon 1-intron 1. Signed log 10 (P value) (SLP) refers to the significance of correlation, with the sign corresponding to the direction of correlation. Details of statistical tests are in Online Methods. Table 1 ). These results suggest that epigenetically controlled regions within MCM6 may mediate individual differences in LCT mRNA expression. We then identified regions involved in the cell-type-specific expression of LCT by comparing the DNA-modification profiles of enterocytes with those of the enterocyte-deficient jejuna from the same individuals. We observed significant differences in DNA modification at 35 CpG sites (P <0.01-10 −14 after Bonferroni correction), which clustered into seven distinct regions: LCT intron 5, intron 3, intron 2 and exon 1, as well as MCM6 exon 17, exon 16 and intron 13 (region size, ~25-560 bp; fold change, 1.35-2.51 between jejunum and enterocytes; Fig. 2a and Supplementary Table 1) . The MCM6 intron 13 and exon 16 regions each overlapped the regions identified in the interindividual analysis above. The LCT exon 1 and intron 2 regions that we identified by targeted bisulfite sequencing were close to the respective regions detected in the tiling microarrays ( Supplementary  Fig. 4c) . Notably, the region in LCT intron 5 mapped to the promoter of the long noncoding RNA (lncRNA) LOC100507600, and the exon 17 region mapped to the 3′ untranslated region (3′ UTR) of MCM6.
We also investigated whether the association of DNA modifications with LCT was unique to enterocytes or could be extended to tissue that does not express LCT mRNA. In white blood cells (from n = 58 individuals), the seven LCT-MCM6 regions were nearly fully modified and therefore vastly differed from those of intestinal tissues (averaged percentage DNA modification in blood, enterocytedeficient jejunum and enterocytes: 73.3% ± 0.4%, 54.2% ± 0.8% and 37.1% ± 0.9%, respectively (mean ± s.e.m.); Supplementary Fig. 5 ). These results provide additional support that these regions facilitate the cell-type specificity of LCT modification.
To further explore the regulatory functions of the differentially modified LCT regions, we investigated chromatin reference maps of the human small intestine ( Fig. 2b and Supplementary Table 2 ) generated by the Epigenomics Roadmap 17, 27, 28 . The discovered regions in LCT exon 1 and introns 2 and 3, as well as MCM6 intron 13, exon 16 and the 3′ UTR overlapped with DNase I-hypersensitivity sites. Moreover, we detected histone modifications characteristic of active enhancers-monomethylated histone H3 K4 (H3K4me1) and acetylated H3 K27 (H3K27ac)-at LCT introns 2 and 3, as well as at MCM6 intron 13, exon 16 and the 3′ UTR. We did not observe any other enhancer sites in a 100-kb region centered over LCT and MCM6. Moreover, LCT exon 1 had an abundance of trimethylated H3 K4 (H3K4me3) and H3K27ac, which are indicative of an active promoter. Hence, functional chromatin signatures corroborate well with the sites that we identified in our DNA-modification study, thus further supporting the role of epigenetic mechanisms in the regulation of LCT.
Genotype-dependent and temporal changes in LCT modification
Because LCT-MCM6 haplotypes exhibit a strong association with lactase nonpersistence and persistence in adult Europeans 5,6,29 , we hypothesized that differential epigenetic modifications might occur in such haplotypes, contributing to the age-dependent regulation of LCT. To test this, we examined whether different genetic backgrounds at LCT-MCM6 led to a divergence of DNA modifications in an agedependent fashion. We first genotyped two MCM6 SNPs (C/T(−13910) (also known as rs4988235) and G/A(−22018) (also known as rs182549)) and an insertion-deletion in the 3′ region of LCT intron 1 in the intestine samples (n = 115 individuals). All three genotypes showed association with steady-state LCT mRNA levels ( Supplementary Fig. 6a ) and exhibited strong pairwise linkage disequilibrium (D′ >0.9; Supplementary Fig. 6b ), results consistent with those from previous reports 5, 6 . Our further analysis focused on the SNP C/T(−13910), for which C and T alleles are part of the haplotypes associated with lactase nonpersistence and lactase persistence, respectively [4] [5] [6] .
We next investigated DNA-modification changes at the seven regulatory regions (described above) in enterocyte samples stratified for genetic background. We observed that CC carriers (lactase nonpersistent), in comparison to TT carriers (lactase persistent), displayed major differences in DNA modification in the MCM6 locus, particularly at MCM6 intron 13-exon 13 (82.1 ± 2.6% versus 19.3 ± 4.1%; P <10 −17 ), where the SNP C/T(−13910) resides ( Fig. 3 and npg a r t i c l e s Supplementary Fig. 6c ). MCM6 intron 13 appears to complete most of its age-dependent epigenetic changes during the first two decades after birth (before the age of the youngest individuals in our sample set, ranging from 21-72 years old). Indeed, changes in DNA modifications at MCM6 intron 13 for the haplotypes containing C(−13910) must occur after conception, because our investigation of sperm samples (n = 18 individuals) revealed no DNA-modification differences among the CC, CT and TT genotypes at this region (>94% modified in all genotypes; data not shown). Such DNA modifications are probably erased at embryogenesis, thus enabling high postnatal LCT activity, and then are gradually regained with age in a haplotypespecific fashion. The situation with MCM6 exon 16 is probably similar, because it also showed significant differences between C(−13910)-and T(−13910)-carrying haplotypes (52.7 ± 3.1% versus 32.8 ± 4.1%; P <0.01; Fig. 3) , although, compared with MCM6 intron 13, it amasses more gradual DNA-modification changes. Molecular events associated with lactase nonpersistence or persistence do not stop at childhood or youth 1,2 . In our cohort of individuals of 21-72 years of age, we detected that LCT mRNA significantly decreased with age in the lactase-nonpersistent, CC individuals (R 2 = 0.2; P <0.01) but showed no aging-related changes in the intermediate (CT) individuals and showed a nonsignificant increase in lactase-persistent, TT individuals (R 2 = 0.13, P = 0.2). We then investigated age-related DNA-modification changes within each of the seven regulatory regions in the enterocyte samples stratified for Figure 4 Aging dynamics of DNA modification at LCT-MCM6 regulatory sites is modified by the SNP C/T(-13910). DNA-modification changes occurring with age, examined in enterocytes of CC, CT and TT carriers (n = 43, 43 and 14 individuals, respectively). Correlations between DNA-modification densities and age at each of the seven epigenetically controlled regions associated with LCT regulation. Region-wide changes, identified by correlations between averaged DNA modification densities at each of the seven regions and age, are indicated by pink (significant; P <0.05) and gray (nonsignificant) boxes. Effects at individual cytosine sites, identified by correlations between single CpGs within each of the seven regions and age, are indicated by red (significant; P <0.05) and black (nonsignificant) bars. In CC individuals, DNA modifications increased with age, an effect most apparent at LCT intron 2 (adjusted R 2 = 0.07) and MCM6 exon 16 (adjusted R 2 = 0.13). DNA modifications in TT individuals primarily decreased with age, except at the lncRNA promoter region which had an age-dependent increase in DNA modifications (adjusted R 2 = 0.28). Correlations between DNA modifications and age, including those that did not reach statistical significance, were predominantly positive in CC individuals and predominantly negative in TT individuals, as indicated by black arrows. R 2 and P values represent significance of correlation coefficient. Source data are available online. (Fig. 4) . In contrast, lactase-persistent, TT individuals showed mostly decreasing DNA modification densities in MCM6 and LCT with age ( Fig. 4) (except at the lncRNA promoter, where greater DNA modification was associated with higher LCT mRNA). DNAmodification changes observed in adulthood may be an extension of the LCT-MCM6 epigenetic processes occurring in childhood. Overall, our findings suggest that lactase nonpersistence may be mediated by an age-related increase in DNA modifications at regulatory elements in MCM6 and LCT, whereas such elements are protected from epigenetic inactivation in lactase-persistent individuals.
Evolutionary conservation of LCT regulation
We next explored the extent of evolutionary conservation of epigenetic factors contributing to the age-dependent downregulation of the lactase gene in mammals. For this, we used 404 padlock probes and bisulfite-sequenced an ~80-kb region containing Lct and Mcm6 in enterocytes of infant (6-d-old) and adult (60-d-old) mice. DNA modifications at Lct introns 2 and 8 (similar regions to those identified in the tiling arrays) significantly increased with age in mice (FDR q <0.05; fold changes, 1.60 and 1.25, respectively; Supplementary Table 1 and Supplementary Figs. 4c and 7a) . Investigation of chromatin marks in ENCODE data of an adult (60-d-old) C57BL/6N mouse identified an enhancer element (H3K27ac and H3K4me1 peaks) in Lct intron 2, along with an active promoter at Lct exon 1-intron 1 (H3K27ac, H3K4me3 and POLR2A peaks) and an inactive enhancer at Mcm6 intron 13 (only H3K4me1; Supplementary Fig. 7b) . Furthermore, the LCT intron 2 region is highly conserved across mammals and contains 7 out of 47 mammalian intronic conserved elements in LCT and MCM6 (139 conserved bases; permutation P <10 −7 ; Supplementary Note 1). We did not find this large degree of mammalian sequence conservation in any other intron of LCT or MCM6 (including MCM6 intron 13). Thus, converging evidence indicates that LCT intron 2 is an evolutionarily old regulatory element that is common in mice and humans (and potentially across all mammals) and contributes to the development of lactase nonpersistence. In contrast, the regulatory regions in MCM6 appear to have emerged more recently and to contribute to lactase persistence in human adults.
lncRNA involvement in LCT expression
We further investigated the contribution of the previously uncharacterized lncRNA LOC100507600 to the regulation of LCT mRNA. LOC100507600 is transcribed from the opposite DNA strand than LCT. Consequently, this lncRNA is probably a natural antisense transcript, a type of regulatory element that can be controlled by DNA modification 30 and that is increasingly being recognized to alter target-gene expression 31, 32 . We examined the human jejunum cohort 2 (n = 59 individuals) and detected a strong positive correlation between expression of LOC100507600 lncRNA and LCT mRNA (R 2 = 0.73; P <10 −9 ; Fig. 5a ).
We next investigated the capacity of the lncRNA to modulate LCT mRNA levels. We performed an RNAi experiment in the human intestinal epithelial cell line Caco-2, which has the TT genotype at SNP C/T(-13910). Transfection with small interfering RNAs (siRNAs) against LOC100507600 decreased expression of LOC100507600 by 20% and resulted in a concomitant 25% decrease in LCT mRNA (P <0.05; Fig. 5b) . Hence, LCT mRNA levels were effectively regulated by this lncRNA in cells relevant to lactase persistence. The mRNA levels of the nontargeted MCM6 remained unchanged by LOC100507600 silencing (Fig. 5b) .
To understand how increased DNA modification at the lncRNA promoter augments LOC100507600 lncRNA and LCT mRNA levels, we surveyed ENCODE data sets 28 . We found a CTCF (insulator)-binding site overlapping the lncRNA promoter that was nearly ubiquitous across human tissues (present in 51 out of 52 cell lines, including Caco-2). Increased DNA methylation inhibits CTCF binding at such insulator sites and consequently activates tissue-specific gene expression 33 and facilitates the interaction of neighboring enhancers with their target promoters 34, 35 . However, further investigation is required to understand this LCT-regulating lncRNA.
Genetic manipulation of lactase regulatory elements
We used CRISPR-Cas9 genome-editing technology to determine whether the differentially modified DNA regions indeed contribute to Lct regulation. To do so, we deleted intronic regions in Lct or Mcm6 and measured the effect on steady-state Lct mRNA (Fig. 6a  and Supplementary Figs. 7b and 8a) . We deliberately targeted only intronic regions, avoiding splicing sites and exons that might compromise Lct mRNA processing and stability. In C57BL/6N mice, we deleted the Lct intron 2 region, which showed evidence of crossspecies lactase-gene regulation, and separately deleted a region in Mcm6 intron 13, which was important in human LCT regulation. We also generated a deletion in Lct intron 1, which served as a positive control because of its overlap with an Lct promoter element. For a negative control, we measured Mcm6 mRNA levels in mice carrying the Mcm6 intron 13 deletion. We also surveyed and did not find any off-target activity of the CRISPR-Cas9 system in 46 candidate regions (Supplementary Fig. 8b,c) .
In adult and infant mice, deletion in Lct intron 1 as well as in Lct intron 2 caused widespread downregulation of Lct throughout the duodenum and jejunum (three-to eight-fold decrease; a b npg a r t i c l e s P <0.001-10 −12 ; Fig. 6b,c) . The deletion in Mcm6 intron 13 yielded less pronounced, segment-specific Lct mRNA decreases (less than two-fold decrease; P <0.05-10 −3 ; Fig. 6b,c) . This intronic deletion did not alter Mcm6 mRNA levels, thus supporting that our CRISPRCas9 deletions specifically affected Lct (Fig. 6b,c) . Compared with the other deletions, the mutation in Lct intron 2 produced a significantly greater loss in Lct mRNA in adults than in infants (two-fold-greater decrease in adult intestine, P <10 −3 ; Fig. 6d ). This result suggests that the evolutionarily conserved Lct intron 2 establishes a stronger control of Lct mRNA in adulthood, thus corroborating our above findings of aging mice. We also examined the extent to which the epigenetically regulated regions affect human LCT expression in cultured Caco-2 human intestinal epithelial cells. Caco-2 cells undergo spontaneous differentiation into enterocyte-like cells of the small intestine when grown past confluence 13 . We assayed LCT expression in Caco-2 cells carrying a CRISPR-Cas9n-induced deletion in the regulatory elements in MCM6 intron 13 or LCT intron 2. We also deleted a region not overlapping a regulatory element in LCT intron 1, which served as a negative control. We examined cells at time points before confluence (undifferentiated, cancer-like state, day 6) and after confluence (differentiated, intestine epithelial-like state, day 15). The deletions did not affect LCT mRNA expression in the undifferentiated state (Fig. 6e) . However, in the differentiated, epithelial-like cell state the deletion in MCM6 intron 13 or LCT intron 2 resulted in a significant decrease in LCT mRNA levels (P <10 −3 ; Fig. 6e ). This finding supports the importance of these regions in the regulation of LCT expression in humans.
DISCUSSION
This study reveals that epigenetic factors are involved in the regulation of the human and mouse lactase genes and, by corollary, the regulation of lactase nonpersistence and related lactose intolerance. DNAmodification studies, in combination with chromatin maps and our functional studies of mutant mice and cell lines, revealed a complex regulation of the lactase gene. Indeed, we found that epigenetic modifications targeting several different regulatory elements account for species-and tissue-specific effects as well as the interindividual variation of LCT expression. A key finding is that different LCT-MCM6 haplotypes exhibit differential epigenetic 'aging' . This result suggests that the epigenetic 'clock' 19 may be individualized by the genetic landscape. Our findings demonstrate that the lactase-nonpersistence haplotypes containing the C(−13910) allele accumulate modified cytosines that silence the regulatory elements in MCM6 and LCT, whereas the lactase-persistence haplotype containing the T(−13910) allele displays age-related modification changes that maintain LCT activity. Because infant LCT mRNA levels are high irrespective of DNA haplotype, DNA variation may not be directly involved in LCT transcription. Instead, genetic variation may mediate the accumulation or loss of epigenetic Relative LCT mRNA levels Fold change
Adults (P60) a r t i c l e s modifications at specific enhancers and promoters, which, in turn, directly orchestrate gene activity. Our study is a first step in understanding the interactions of genetic and epigenetic mechanisms in lactase-gene regulation. Previous studies have reported that differences in transcription-factor binding occur together with chromosome-wide changes in DNA modifications during the differentiation of enterocytes along the crypt-to-villi axis, a process necessary for LCT expression along this axis 36, 37 . In addition, SNPs associated with lactase persistence and nonpersistence show allelic differences in transcription-factor binding, whereby Oct-1, in combination with HNF1α, shows a higher affinity toward the T(−13910) allele than toward the C allele 15, 38 . Recently, the DNA-methylation machinery has been found to compete with transcription-factor binding in vivo 39 . Therefore, the age-dependent accumulation of modified cytosines at LCT-MCM6 regulatory elements may be circumvented in the lactase-persistence T(−13910) allele, owing to its higher affinity for transcription-factor binding. In addition, differences in DNA modification among LCT-MCM6 haplotypes may influence the extent of CTCF binding, thus affecting chromatin conformation and consequently the accessibility of regulatory elements 34, 35, 40 . Indeed, our analysis of ENCODE data reveals an enrichment of CTCF-binding sites at the lncRNA promoter and other regions, including MCM6 intron 13. Future studies examining chromatin configuration 35 at the LCT-MCM6 locus in aging individuals and targeted epigenetic editing with the CRISPR-Cas9 system 41 will be necessary to fully understand the genetic and epigenetic contributions to lactase persistence and nonpersistence.
Our study helps to further delineate the principles and guidelines for epigenomic studies of other traits and diseases. The main lessons learned are: (i) the specific cell type centrally involved in the phenotype rather than bulk tissues or organs must be investigated; (ii) quantitative phenotypes and endophenotypes (in this case mRNA levels) should be used; (iii) sites containing stretches of differentially modified CpGs are replicable and more biologically plausible than solitary CpGs (a consideration affecting single-CpG detection methods, e.g., Illumina 450K arrays); (ii) cross-species comparisons (in this case showing partial conservation of regulatory elements between mice and humans) are beneficial; (v) examination of multiple epigenetic layers yields insight into regulatory-element functions; and (vi) DNAsequence risk factors, in close association with epigenetic abnormalities, may influence gene-regulatory elements.
The reach of this study may extend far beyond the lactose-related phenotype and might benefit etiological investigations of complex aging diseases, such as cancer, type 2 diabetes and Alzheimer's disease. The necessity of both genetic and epigenetic components in disease etiology may account for why genetic risk factors without their age-dependent epigenetic 'load' can remain harmless for numerous decades. In our study, we found that genetic variation appears to set the stage, either allowing or preventing accumulation of DNA modifications with age at key regulatory sites. In late-onset diseases, DNA variants may become bona fide disease risk factors once they reach a critical mass of epigenetic misregulation in aging cells. Genetic-epigenetic interactions may also be involved in the age-dependent loss of pathogenicity of risk genes (e.g., recovery from childhood asthma, epilepsy and atopic dermatitis in adults 42, 43 ). Thus, investigation of age-dependent epigenetic trajectories for disease-associated genetic variants may be essential to uncovering the molecular origins of complex diseases.
METhODS
Methods and any associated references are available in the online version of the paper. Modification estimates were considered only if 30 or more reads spanned the cytosine. CpG sites were filtered for effect size (interquartile range ≥0.05) and sparsity (coverage in ≥30 samples). In the human samples, we excluded CpG sites within 1 bp of common polymorphisms called as part of the 1000 Genomes Project 50 (phase 3, v5a release).
For analysis of the human samples, the correlation was measured between the DNA-modification density at individual CpGs and relative steady-state LCT mRNA with Kendall's nonparametric correlation test. Bonferroni multiple testing correction was then performed, and CpGs were considered to be significant at a familywise error-rate threshold of α <0.01. CpGs exhibiting cell-type-specific expression were identified by performing a nonparametric Mann-Whitney test at each CpG between the sets of enterocyte and enterocyte-deficient jejunum samples, and then a Bonferroni multiple testing correction was applied, with a significance threshold of α <0.01.
For mouse samples, the significance of association between DNA modifications and age was measured separately at each CpG by comparing the modification levels of postnatal day 6 and day 60 mice with a Mann-Whitney nonparametric test. Multiple testing correction was performed by using the Benjamini-Hochberg method with an FDR threshold of q <0.05.
Analysis of chromatin state. NarrowPeak peak calls were downloaded for four tracks (DNase, H3K4me1, H3K4me3 and H3K27ac; Supplementary 51 ). LCT-associated regions smaller than 500 bp were symmetrically extended to 500 bp. A 100-kb region encompassing LCT and MCM6 (chromosome 2, 136540000-136640000) was scanned for potential enhancer regions by identification of all overlapping H3K4me1 and H3K27ac peaks annotated with an FDR q <0.01. For the mouse small intestine, we obtained processed data, including BroadPeak calls, for four tracks (POLR2A, H3K4me1, H3K4me3 and H3K27ac) from ENCODE (https://www.encodeproject.org/). These originated from the small intestine of 60-day-old C57BL/6NCrl mice (the same age and strain as those used in the bisulfite padlock-probe sequencing). Peak calls were lifted over from mm9 to mm10 with the UCSC LiftOver tool and then intersected with the interrogated 80-kb region containing Lct and Mcm6 (chromosome 1m 128280000-128360000).
Analysis of mammalian sequence conservation. The significance of intronic conservation within mammals was assessed with 12-mer constraint predictions from a multiple sequence alignment of sequences from 29 mammals 52 (http://www.broadinstitute.org/ftp/pub/assemblies/mammals/29mammals/ hg19/hg19_29way_pi_lods_elements_12mers.chr_specific.fdr_0.1_with_scores. txt.gz). Intronic regions were defined as the intervals of Refgene regions at least 100 bp away from the nearest exon and within a 100-kb region centered on LCT and MCM6 (chromosome 2, 136540000-136640000), thus resulting in 33 intronic intervals spanning 67,744 bp. Mammalian conserved elements were intersected with these intronic intervals with bedtools to identify 47 intronic conserved elements within LCT and MCM6 (758 conserved bases, or 1.12% of intronic sequence). The expected number of conserved bases within a 500-bp window was modeled by randomly permuting the locations of the 47 conserved elements within the intronic intervals with bedtools shuffle and measuring the total number of conserved bases within a 500-bp region, for each of 10,000,000 iterations. A set of 25 overlapping 500-bp windows were sufficient to span all 47 conserved elements, and the significance of each window was measured by comparing the number of conserved bases within the window to the permuted distribution.
RNA interference. The relationship between lncRNA (LOC100507600) and LCT mRNA levels was examined by RNA interference in Caco-2 cells (ATCC). For this approach, Caco-2 cells were transfected with either an equimolar pool of four siRNAs (30 pmol) directed against LOC100507600 (Qiagen FlexiTube GeneSolution; SI05737893, SI05737900, SI0737907 and SI0737914) or a scrambled control siRNA (Qiagen AllStars Neg. siRNA AF488, SI03650318) with RNAiMAX (Life Technologies), according the manufacturer's instructions (Supplementary   Note 2) . The siRNA or scrambled-control group was randomly assigned to each cell well. After 48 h, transfection efficiency was confirmed for siRNAs conjugated to AlexaFluor-488 with an Olympus FV1200 confocal microscope and FluoView 1200 software (Olympus). Cells were then harvested, and RNA was extracted with TRIzol reagent (Life Technologies). mRNA levels were analyzed by qPCR, as described above, to evaluate the consequence of LOC100507600 knockdown on LCT expression. CRISPR-Cas9 genome editing. Genetic deletions in the Mcm6 intron 13, Lct intron 2 or Lct intron 1 of mice were generated with the CRISPR-Cas9 genome editing technique, as previously described 53 . Design of sgRNAs targeting these loci was completed with the MIT CRISPR Design tool 53 . Guides were selected on the basis of highest on-target specificity and avoided exons, intronic regions adjacent to exons (at least 100 bp), and repetitive regions.
For the Cas9 RNA-guided nuclease-modified mice, sgRNA templates for in vitro transcription were amplified by high-fidelity PCR with a forward primer with the T7 promoter, the guide RNA sequence, and an anchor sequence for the pX330 plasmid (gift from F. Zhang, Addgene 42230) and a reverse primer at the 3′ terminus of the sgRNA sequence in pX330 (primers detailed in Supplementary Table 3 ). The PCR templates were gel-purified, used for in vitro transcription with a MEGAshortscript T7 transcription kit (Life Technologies) and purified with a MEGAclear kit (Life Technologies). Cas9 mRNA was produced by in vitro transcription of a T7-promoter-containing amplicon from pX330 by using a mMESSAGE mMACHINE T7 Ultra Kit (Life Technologies). Cas9 mRNA (20 ng/µL) and sgRNA (10 ng/µL) were premixed in injection buffer (10 mM Tris and 0.1 mM EDTA, pH 7.5) and microinjected via continuous flow into the pronuclei of C57BL/6NCrl zygotes at the Toronto Centre for Phenogenomics, Canada. Mutation success rates were 18% for Mcm6 (n = 2 mice), 11% Lct intron 1 (n = 2) and 38% for Lct intron 2 (n = 5). F 0 mice were backcrossed to wild-type C57BL/6NCrl mice, and F 1 heterozygous mice were intercrossed, keeping each founder line separate. Of the nine mutant lines, we investigated only one for each Mcm6 and Lct intron 1, and three lines for Lct intron 2 (the three Lct intron 2 lines did not differ; Supplementary Fig. 8d ). F 2 offspring from the heterozygous mouse intercrosses were used in experiments.
For genetic modifications in the Caco-2 cell line (ATCC), a model of human intestinal epithelial cells, we used the CRISPR-Cas9n system, which has been shown to increase genome editing specificity in cells 54 . We generated homozygous deletions in MCM6 intron 13, LCT intron 2 or LCT intron 1 in the human cells with a CRISPR-Cas9n protocol described previously 53 and in Supplementary Note 2. Caco-2 cells in the CRISPR-Cas9n and RNAi experiments were authenticated and showed a 100% match to the reference profile of Caco-2 (ATCC HTB-37), on the basis of genetic analyses of 15 autosomal tandem-repeat loci and the gender-identity locus amelogenin (performed by Genetica DNA Laboratories). A PCR-based test with an eMYCO Plus kit (iNtRON Biotechnology) verified the absence of mycoplasma contamination in the Caco-2 cells used (performed by Genetica DNA Laboratories).
CRISPR-induced deletions in both the mice and Caco-2 cells were confirmed by Sanger sequencing (ACGT Corporation, Toronto, Canada). LCT steadystate mRNA levels were measured in the CRISPR-Cas9-modified mice and CRISPR-Cas9n-modified Caco-2 cells with a qPCR assay (described above and in Supplementary Note 2).
Genotyping and analysis of CRISPR-induced deletions. Human jejunum samples were genotyped for the genetic variants C/T(−13910), G/A(−22018) and the deletion in LCT intron 1. PCR amplicons were generated with a KAPA2G Fast kit (Kapa Biosystems), as described in Supplementary Note 2. Genetic variants were identified on the basis of Sanger sequencing (C/T(−13910); ACGT Corporation, Toronto, Canada), restriction endonuclease digestion with BstUI (G/A(−22018); NEB) or PCR-amplicon size 5 (deletion in LCT intron 1). The linkage disequilibrium and haplotype structure between these genetic variants were examined with Haploview 4.2.
For the CRISPR-Cas9-modified mice, genotyping was conducted with genomic DNA isolated from mice tail clippings with a standard high-salt method. For the CRISPR-Cas9n modifications in Caco-2 cells, genomic DNA was isolated for each cell colony with QuickExtract solution (Epicentre). Genomic DNA from mice or cells was PCR-amplified with Herculase II Fusion DNA polymerase (Agilent Technologies), as described in Supplementary
